WASHINGTON, Nov. 29, 2022 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced that Chief Executive Officer Seth Blackley, Chief Financial Officer John Johnson and Vice President, Investor Relations Seth Frank will participate in upcoming investor conferences.
A live audio-only webcast and replay for these events will be available on the Investor Relations section of Evolent's website at http://ir.evolenthealth.com/, unless otherwise noted below.
Evolent Health delivers proven clinical and administrative solutions that improve whole-person health while making health care simpler and more affordable. Our solutions encompass total cost of care management, specialty care management and administrative simplification. Evolent serves a national base of leading payers and providers, is the first company to receive the National Committee for Quality Assurance's Population Health Program Accreditation and is consistently recognized as a top place to work in health care nationally. Learn more about how Evolent is changing the way health care is delivered by visiting evolenthealth.com.
Contacts:
Seth R. Frank
Vice President, Investor Relations
Evolent Health, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
571-895-3919 (W)
Last Trade: | US$30.51 |
Daily Change: | 0.16 0.53 |
Daily Volume: | 1,348,552 |
Market Cap: | US$3.550B |
August 08, 2024 June 04, 2024 May 09, 2024 May 09, 2024 February 22, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB